CompletedNCT01895452
ALKS 9072 Long-Term Safety in Schizophrenia
About this title
Read the official source — NCT01895452Researchers compared ALKS 9072, Low Dose and ALKS 9072, High Dose, tracking side effects to assess long-term safety in people with schizophrenia.
Medication studyAges 18–70Multiple countries
Understand this study
What did researchers investigate?
Researchers compared ALKS 9072, Low Dose and ALKS 9072, High Dose, tracking side effects to assess long-term safety in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 56 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 291
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Malaysia, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT01895452
- Official title
Show the full official title
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedLittle Rock, United States · Garden Grove, United States · Oakland, United States
52 more locations
- Oceanside, United States
- Orange, United States
- Washington D.C., United States
- Fort Lauderdale, United States
- Leesburg, United States
- Atlanta, United States
- Chicago, United States
- Hoffman Estates, United States
- Shreveport, United States
- Oklahoma City, United States
- Dallas, United States
- Burgas, Bulgaria
- Novi Iskar, Bulgaria
- Pazardzhik, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Cheras, Malaysia
- Johor Bahru, Malaysia
- Kuala Lampur, Malaysia
- Kuching, Malaysia
- Mariveles, Philippines
- Cebu City, Philippines
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Manila, Philippines
- Bucharest, Romania
- Oradea, Romania
- Târgu Mureş, Romania
- Roshchino, Russia
- Lipetsk, Russia
- Moscow, Russia
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Stavropol, Russia
- Talagi, Russia
- Yaroslavl, Russia
- Jeollanam-do, South Korea
- Chernihiv, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Poltava, Ukraine
- Ternopil, Ukraine
- Vinnytsia, Ukraine
- Russia
Questions about this study
What did researchers investigate?
Researchers compared ALKS 9072, Low Dose and ALKS 9072, High Dose, tracking side effects to assess long-term safety in people with schizophrenia.
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including ALKS 9072, Low Dose and ALKS 9072, High Dose.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia